Genesis Pharma
Genesis Pharma is a privately-held biopharmaceutical commercialization company that serves as the exclusive regional commercial partner for global biotech and pharma innovators, commercializing innovative therapies for chronic and rare diseases across 17 European markets.
- Company typePrivate
- Founded1997
- HeadquartersKifisiá, Greece
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Genesis Pharma does
Genesis Pharma is a privately-held biopharmaceutical commercialization company headquartered in Kifisiá (Chalandri), Athens, Greece, founded in 1997. The company operates as an exclusive regional commercial partner for leading global biotech and pharmaceutical innovators, commercializing their innovative therapies for chronic and rare diseases across Central and Eastern Europe and, since June 2026, the Nordic region. It does not develop proprietary molecules or own manufacturing; instead, it secures exclusive licensing and distribution rights and executes the full commercial stack, including market access, regulatory affairs, pricing and reimbursement, medical affairs, sales and marketing, distribution, and pharmacovigilance.
The portfolio comprises partner-sourced products spanning hematology, oncology, immunology, inflammatory diseases, neurology, rheumatology, and rare/orphan diseases, including RNAi therapeutics (Alnylam), gene therapy (Krystal Biotech), FLT3 inhibitors (Daiichi Sankyo), dissociative corticosteroids (Santhera), PD-1 inhibitors (Regeneron), kinase inhibitors (Deciphera, Incyte), and orphan biologics (Kyowa Kirin, Amicus). Distribution is executed through a network of wholly-owned subsidiaries in 11 jurisdictions plus a Cyprus-based intermediate holding company, with additional coverage in the Baltics, Western Balkans, and Malta operated from regional hubs. The company also maintains certified quality (ISO 9001), information security (ISO 27001), and anti-bribery (ISO 37001) management systems.
The business model is fee-and-margin-based commercialization under exclusive license and supply agreements with global pharma partners, with revenue generated through product sales, distribution margins, and commercialization services. Pricing is determined country-by-country through national regulatory and reimbursement processes and is not publicly disclosed. Customers in a B2B sense are the global pharma partners that license products to Genesis Pharma, while B2C demand is generated through healthcare professionals, hospitals, and specialty treatment centers across 17 European markets. The company employs approximately 200 people, the majority based in Greece, and reports no external institutional or private-equity ownership.
Genesis Pharma firmographics
Firmographics- Name
- Genesis Pharma
- Legal name
- GENESIS PHARMA S.A.
- Website
- https://genesispharma.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Genesis Pharma is a privately-held biopharmaceutical commercialization company that serves as the exclusive regional commercial partner for global biotech and pharma innovators, commercializing innovative therapies for chronic and rare diseases across 17 European markets.
- Ownership category
- akta.pro rank
Genesis Pharma industry classification
Industry- Product category
- Biopharmaceutical Commercialization Services
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
- akta.pro secondary industry
- Biologics & Biosimilars Distributors (HLAIAJAH)
Keywords
Where Genesis Pharma is headquartered
LocationHeadquarters
- HQ city
- Kifisiá
- HQ country
- Greece
- HQ region
- Europe
Offices14 records
Markets served
Genesis Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Marketing or Sales, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- Product commercialization and distribution: GENESIS Pharma generates revenue by commercializing biopharmaceutical products under exclusive distribution and licensing agreements with global pharmaceutical and biotech companies. The company handles sales, marketing, medical affairs, regulatory affairs, pricing, and reimbursement across its geographic territory.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Genesis Pharma product offering
Product offeringCore offering
Genesis Pharma is a biopharmaceutical commercialization company that commercializes, promotes, distributes, and sells innovative medicines for chronic and rare diseases under exclusive licensing and supply agreements with global pharmaceutical and biotech partners. The company manages the full commercial lifecycle—sales, marketing, medical affairs, regulatory affairs, pricing, and reimbursement—across 17 European markets, serving as the regional commercial partner of choice for partners including Alnylam, Daiichi Sankyo, Otsuka, Krystal Biotech, Santhera, Regeneron, Deciphera, Incyte, Kyowa Kirin, and Amicus.
Product overview
GENESIS Pharma is a regional biopharmaceutical company that operates as a commercial partner for leading international biotech and pharmaceutical companies, specializing in the commercialization of innovative medicines for chronic and rare diseases in Central and Eastern Europe. The company does not develop its own drugs but instead secures exclusive rights to commercialize products from global partners including Alnylam (RNAi therapeutics), Daiichi Sankyo (quizartinib), Otsuka (donidalorsen), Krystal Biotech (beremagene geperpavec), Santhera (vamorolone), Regeneron (cemiplimab), Deciphera (ripretinib), Incyte (ponatinib, pemigatinib, tafasitamab), Kyowa Kirin (burosumab, mogamulizumab), and Amicus (migalastat). The portfolio covers therapeutic areas including hematology, oncology, immunology, inflammatory diseases, rare diseases, neurology, and rheumatology, with expertise in biopharmaceuticals and innovative orphan drugs.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Expanded partnership with Alnylam to cover 17 total markets including 4 Nordic countries
- +1 more outcomes
Companies that use Genesis Pharma
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Genesis Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Genesis Pharma partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core.
- Alnylam PharmaceuticalscoreGENESIS Pharma serves as the exclusive commercial partner for Alnylam's RNAi therapeutics portfolio across 17 markets in Europe (13 Southeast European markets plus 4 Nordic markets: Denmark, Finland, Norway, Sweden). The partnership, originally established in 2019, covers RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases. Alnylam is a commercial-stage biopharmaceutical company with six approved medicines and reported 83% revenue growth.
- Daiichi SankyocoreExclusive license and supply agreement for the distribution and commercialization of VANFLYTA (quizartinib) across 13 Central and Eastern European markets for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia. Daiichi Sankyo handles manufacturing and supply while GENESIS Pharma leads commercialization efforts in markets including Bulgaria, Croatia, Poland, Romania, and nine other countries.
- Otsuka Pharmaceutical Europe Ltd.coreExclusive agreement for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe. The agreement covers 14 markets. The European Commission's review of the drug's authorization is ongoing as of December 2025.
- Krystal BiotechcoreExclusive agreement for the distribution and commercialization of beremagene geperpavec-svdt (B-VEC), a topical gene therapy for dystrophic epidermolysis bullosa, across 12 Central and Eastern European markets including Greece, Cyprus, Romania, Bulgaria, Croatia, Malta, Serbia, North Macedonia, Bosnia & Herzegovina, Montenegro, Albania, and Kosovo.
- Santhera PharmaceuticalscoreExclusive commercial agreement for vamorolone for Duchenne Muscular Dystrophy treatment across 20 markets in Central and Eastern Europe, including Greece, Cyprus, Malta, Romania, Bulgaria, Slovenia, Croatia, Poland, Czech Republic, Hungary, Slovakia, Lithuania, Latvia, Estonia, Serbia, North Macedonia, Bosnia-Herzegovina, Montenegro, Albania, and Kosovo.
- Regeneron Pharmaceuticals (via Regeneron Ireland DAC)coreExclusive distribution agreement for cemiplimab (PD-1 inhibitor) in Greece, Cyprus, and Malta for the treatment of advanced basal cell carcinoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, and cervical cancer.
- Deciphera PharmaceuticalscoreExclusive distribution agreement for ripretinib (QINLOCK) for fourth-line treatment of gastrointestinal stromal tumor (GIST) across 14 Central and Eastern European markets including Greece, Cyprus, Bulgaria, Estonia, Croatia, Latvia, Lithuania, Malta, Hungary, Poland, Romania, Slovakia, Slovenia, and Czech Republic.
- Kyowa KirincoreCommercial partnership for orphan drug portfolio in Greece, Cyprus, and Malta. GENESIS Pharma commercializes burosumab for X-linked hypophosphatemia and tumor-induced osteomalacia, and mogamulizumab for cutaneous T-cell lymphoma subtypes.
- Incyte Biosciences International SàrlcoreExpansion of exclusive supply and distribution agreement covering ponatinib plus two new oncology drugs (pemigatinib and tafasitamab) across 11 markets including Greece, Cyprus, Croatia, Slovenia, Malta, Serbia, North Macedonia, Bosnia-Herzegovina, Kosovo, Albania, and Montenegro. Original six-year collaboration began in 2016.
- SeagencoreExclusive collaboration for an innovative oncology therapy for HER2-positive, locally advanced or metastatic breast cancer in Greece, Cyprus, and Malta.
- Jazz PharmaceuticalscoreExclusive collaboration for an oncology treatment for high-risk acute myeloid leukemia (t-AML and AML-MRC) in Greece, Cyprus, and Malta.
- Amicus TherapeuticscoreExclusive rights to commercialize migalastat in Greece, Cyprus, Romania, and Bulgaria for the treatment of Fabry disease. GENESIS Pharma is responsible for sales, marketing, medical affairs, regulatory, and reimbursement support. The European Commission granted full approval for migalastat in May 2016.
- BiogencoreListed as a partner on the company website. Biogen is a leading global biopharmaceutical company with products in neurology, immunology, and rare diseases.
- CSL ViforcoreListed as a partner on the company website. CSL Vifor specializes in rare diseases, transplant, and cardio-renal therapies.
- Pharma MarcoreListed as a partner on the company website. Pharma Mar is a Spanish biopharmaceutical company focused on oncology.
- Regeneron (additional reference)coreListed as a partner on the company website (in addition to the formalized Seagen partnership).
- Krystal BiocoreListed as a partner on the company website (partner for gene therapy beremagene geperpavec).
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Genesis Pharma competitors and assessment
Company assessmentDirect peers
- Swixx BioPharma: Switzerland-based biopharma commercialization company that partners with global pharma and biotech to launch and commercialize products across CEE, CIS, and MEA — directly comparable business model to GENESIS.
- Ewopharma: Swiss-headquartered specialty biopharma commercialization partner focused on Central and Eastern Europe, operating a similar regional exclusive-distribution and market-access model with global pharma partners.
Emerging players
- NewBridge Pharmaceuticals: Dubai-based regional biopharma commercialization partner focused on the Middle East and Africa, operating the same 'exclusive partner for global pharma in emerging markets' model as GENESIS but in a different geography.
- Biopas Laboratories: LATAM-focused biopharma commercialization and distribution partner representing global pharma companies, structurally similar to GENESIS in providing regional market access for international specialty drug portfolios.
Broad incumbents
- Gedeon Richter: Hungary-headquartered major pharmaceutical company with deep CEE presence and a specialty/biologics portfolio — broader and vertically integrated but operates in the same CEE geographies and therapeutic areas as GENESIS.
- KRKA: Slovenia-based pharmaceutical manufacturer with strong CEE and Eastern European commercial reach — competes for the same regional distribution relationships and pharmacy/payer relationships as GENESIS.
- Egis Pharmaceuticals: Hungary-based pharmaceutical group with broad CEE distribution and specialty pharma presence — comparable CEE footprint and channel relationships, though with proprietary products rather than the pure distribution model.
- Zentiva: Czech Republic-based European generics and specialty pharma company with significant CEE presence — comparable regional channel and market-access footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Genesis Pharma social profiles
Digital presenceGenesis Pharma compliance and trust
Trust signalCompliance8 records
Genesis Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genesis Pharma leadership team
Management profileNumber of profiles
Profiles1 record
Genesis Pharma subsidiaries and ownership
Company hierarchySubsidiaries11 records
Genesis Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genesis Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genesis Pharma
What does Genesis Pharma do?
Genesis Pharma is a biopharmaceutical commercialization company that commercializes, promotes, distributes, and sells innovative medicines for chronic and rare diseases under exclusive licensing and supply agreements with global pharmaceutical and biotech partners. The company manages the full commercial lifecycle—sales, marketing, medical affairs, regulatory affairs, pricing, and reimbursement—across 17 European markets, serving as the regional commercial partner of choice for partners including Alnylam, Daiichi Sankyo, Otsuka, Krystal Biotech, Santhera, Regeneron, Deciphera, Incyte, Kyowa Kirin, and Amicus.
Is Genesis Pharma a public or private company?
Genesis Pharma is a private company. It is classified as unknown and is currently operating.
When was Genesis Pharma founded?
Genesis Pharma was founded in 1997. It employs 101 to 250 people.
Where is Genesis Pharma based?
Genesis Pharma is headquartered in Kifisiá, Greece, in the Europe region.
How does Genesis Pharma make money?
One revenue line is on record: product commercialization and distribution.
Who are Genesis Pharma's main competitors?
Direct peers on record are Swixx BioPharma and Ewopharma. Emerging players are NewBridge Pharmaceuticals and Biopas Laboratories. Broad incumbents are Gedeon Richter, KRKA, Egis Pharmaceuticals and Zentiva.
Does Genesis Pharma have an API?
No public API is recorded for Genesis Pharma.
What industry is Genesis Pharma in?
Genesis Pharma's product category is Biopharmaceutical Commercialization Services. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant), with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 424210 and its SIC code is 5122.